Angiogenesis Inhibitors |
AMG-386 |
Peptibody disrupting interaction between Ang-1/2 and Tie-2. |
|
CVX-060 |
Fusion protein comprised of two Ang-2 binding peptides |
|
CVX-241 |
Fusion protein with affinity for both VEGF and Ang-2 |
|
Thalidomide |
Immunomodulator; precise mechanism unknown |
|
Lenalidomide |
Immunomodulator; precise mechanism unknown |
Immunotherapy |
BMS-936558 (MDX-1106) |
Fully human IgG4 blocking PD-1 |
|
IMA901 |
Vaccine derived from TAAs, including 9 HLA-class I and 1 HLA- class II binding peptides |
|
AGS-003 |
Autologous dendritic cell vaccine generated through electroporation of tumor-derived RNA and CD40L |
|
MGN-1601 |
Allogeneic vaccine comprised of human RCC cells modified to express IL-7, GM-CSF, CD80, and CD154 |
|
Ipilimumab |
Monoclonal antibody with affinity for CTLA4 |
Cytotoxic Therapy |
S-1 |
Oral formulation comprised of tegafur, potassium oxonate, and 5- choloro-2,4-dihydroxypyridine |
|
Ixabepilone |
Novel epothilone inhibiting microtubule function |
Targeted Agents |
XL184 |
Small molecule inhibitor of VEGFR2 and MET |
|
ARQ197 |
Small molecule inhibitor of MET |
|
AMG-102 |
Monoclonal antibody with affinity for HGF |
|
Dovitinib (TKI-258) |
Small molecule inhibitor of FGFR1-3 |
|
Brivanib |
Small molecule inhibitor of VEGFR and FGFR1-3 |